title: [A statistical study of management based on prognostic factors after surgical treatment for cervical carcinoma].
abstract: In order to improve the therapeutic results after surgical treatment for cervical carcinoma, 236 patients treated from 1969 to 1976, who could be followed up for five years, were analyzed retrospectively. Various prognostic factors were studied by principal component analysis (quantification method III), and criteria of risk of recurrence were established. Using the discriminant function obtained, another series of 246 patients treated surgically experienced from 1977 to 1982, whose clinical stages were Ib or more, were divided into three groups according to the risk of recurrence and were managed accordingly. The patients in groups II and III, in whom recurrence was possible, received continuous adjuvant chemotherapy with Tegafur (400-600mg/day). The results obtained were as follows. In the principal component analysis, coefficients for the clinical stage, invasion into the parametrium, location of carcinoma and invasion into the uterine body were high on the X1-axis, considered to represent the tumor volume. On the X2-axis, considered to represent the tumor biological characteristics, coefficients of the histological type, CPL classification and lymph node metastasis were high. The risk of recurrence was calculated by the following discriminant function; Z = 0.810X1 + 0.710X2. The values obtained were Z less than 0.053 in group I, 0.053 less than or equal to Z less than 0.376 in group II and Z greater than or equal to 0.376 in group III. Using the equation, 246 cases from 1972 to 1982 were prospectively divided into three groups.(ABSTRACT TRUNCATED AT 250 WORDS)
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D000284:Administration, Oral; D000328:Adult; D000367:Age Factors; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology*; D011184:Postoperative Period; D011379:Prognosis; D005641:Tegafur / Q000008:administration & dosage; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*
chemical_list: D005641:Tegafur